| Title |
Cannabinoids and agmatine as potential therapeutic alternatives for cisplatin-induced peripheral neuropathy
|
|---|---|
| Published in |
Journal of experimental pharmacology, June 2018
|
| DOI | 10.2147/jep.s162059 |
| Pubmed ID | |
| Authors |
Basak Donertas, Cigdem Cengelli Unel, Kevser Erol |
| Abstract |
Cisplatin is a widely used antineoplastic agent in the treatment of various cancers. Peripheral neuropathy is a well-known side effect of cisplatin and has the potential to result in limiting and/or reducing the dose, decreasing the quality of life. Unfortunately, the mechanism for cisplatin-induced neuropathy has not been completely elucidated. Currently, available treatments for neuropathic pain (NP) are mostly symptomatic, insufficient and are often linked with several detrimental side effects; thus, effective treatments are needed. Cannabinoids and agmatine are endogenous modulators that are implicated in painful states. This review explains the cisplatin-induced neuropathy and antinociceptive effects of cannabinoids and agmatine in animal models of NP and their putative therapeutic potential in cisplatin-induced neuropathy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 10% |
| Researcher | 3 | 10% |
| Student > Ph. D. Student | 3 | 10% |
| Lecturer | 2 | 6% |
| Student > Bachelor | 2 | 6% |
| Other | 3 | 10% |
| Unknown | 15 | 48% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 19% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Psychology | 2 | 6% |
| Social Sciences | 1 | 3% |
| Other | 3 | 10% |
| Unknown | 14 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2018.
All research outputs
#16,868,837
of 25,584,565 outputs
Outputs from Journal of experimental pharmacology
#65
of 147 outputs
Outputs of similar age
#210,887
of 343,364 outputs
Outputs of similar age from Journal of experimental pharmacology
#2
of 4 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 147 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,364 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.